Program for Prostate Cancer Screening Using a Mobile Unit: Results From Brazil

被引:26
作者
Faria, Eliney F.
Carvalhal, Gustavo F.
Vieira, Rene A. C.
Silva, Thiago B.
Mauad, Edmundo C.
Carvalho, Andre L.
机构
[1] Barretos Canc Hosp, Canc Prevent Dept, Sao Paulo, Brazil
[2] Barretos Canc Hosp, Researcher Support Ctr, Div Urol, Sao Paulo, Brazil
[3] Univ Sao Paulo, Postgrad Program, Sao Paulo, Brazil
关键词
DIGITAL RECTAL EXAMINATION; MULTICENTER CLINICAL-TRIAL; 4.0; NG/ML; FREE PSA; ANTIGEN; MORTALITY; MEN; DECREASE; CUTOFF; STATES;
D O I
10.1016/j.urology.2010.02.044
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To evaluate the initial results of a prostate cancer screening program using mobile units in Brazil. METHODS Since 2004, we have conducted a program of prostate cancer screening using mobile units across 231 municipalities from 6 Brazilian states. RESULTS A total of 17 571 men were evaluated by clinical history, digital rectal examination (DRE), and serum free and total prostate-specific antigen (PSA) levels. The recommendations for biopsy were a PSA level of >= 4.0 ng/mL, DRE findings suspicious for cancer, or a PSA level of 2.5-4.0 ng/mL with a percent-free PSA level <15%. The biopsy protocol included 12 biopsy cores from the peripheral zone, 2 from the transition zone, and additional sampling of suspicious areas. The cumulative cancer detection rate was 3.7%. The main indication for biopsy was a PSA level of >= 4.0 ng/mL (51.2%), with a positive predictive value (PPV) of 44.1%. Another 19.7% of biopsied men had suspicious DRE findings with a normal PSA level (PPV 23.5%). A percent-free PSA level of <15% in men with a PSA level of 2.5-4.0 ng/mL and normal DRE findings yielded a PPV of 31.1%. The PPV was greater (70.9%) for the 7.1% of men with both suspicious DRE findings and a PSA level of >4.0 ng/mL. Most cancers were Stage T1-T2 (93.4%), and the percentage of Gleason score of >= 7 was 32.5%. The proportion of insignificant cancers according to Epstein's criteria was 13.5%. CONCLUSIONS A mobile prostate cancer screening unit enabled an underserved population to gain access to specialized care through the public healthcare system. The cancer detection rate in this population was similar to those from international studies. UROLOGY 76: 1052-1057, 2010. (C) 2010 Published by Elsevier Inc.
引用
收藏
页码:1052 / 1057
页数:6
相关论文
共 30 条
[1]   Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].
Andriole, Gerald L. ;
Grubb, Robert L., III ;
Buys, Saundra S. ;
Chia, David ;
Church, Timothy R. ;
Fouad, Mona N. ;
Gelmann, Edward P. ;
Kvale, Paul A. ;
Reding, Douglas J. ;
Weissfeld, Joel L. ;
Yokochi, Lance A. ;
Crawford, E. David ;
O'Brien, Barbara ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hayes, Richard B. ;
Kramer, Barnett S. ;
Izmirlian, Grant ;
Miller, Anthony B. ;
Pinsky, Paul F. ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319
[2]   Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial [J].
Andriole, GL ;
Levin, DL ;
Crawford, ED ;
Gelmann, ER ;
Pinsky, PF ;
Chia, D ;
Kramer, BS ;
Reding, D ;
Church, TR ;
Grubb, RL ;
Izmirlian, G ;
Ragard, LR ;
Clapp, JD ;
Prorok, PC ;
Gohagan, JK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) :433-438
[3]  
[Anonymous], PROST SPEC ANT BEST
[4]   Population-based case-control study of PSA and DRE screening on prostate cancer mortality [J].
Bergstralh, Eric J. ;
Roberts, Rosebud O. ;
Farmer, Sara A. ;
Slezak, Jeffrey M. ;
Lieber, Michael M. ;
Jacobsen, Steven J. .
UROLOGY, 2007, 70 (05) :936-941
[5]   Recent trends in prostate cancer mortality show a continuous decrease in several countries [J].
Bouchardy, Christine ;
Fioretta, Gerald ;
Rapiti, Elisabetta ;
Verkooijen, Helena Maria ;
Rapin, Charles Henry ;
Schmidlin, France ;
Miralbell, Raymond ;
Zanetti, Roberto .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (02) :421-429
[6]   Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less [J].
Carvalhal, GF ;
Smith, DS ;
Mager, DE ;
Ramos, C ;
Catalona, WJ .
JOURNAL OF UROLOGY, 1999, 161 (03) :835-839
[7]   Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging [J].
Catalona, WJ ;
Southwick, PC ;
Slawin, KM ;
Partin, AW ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Gasior, GH ;
Loveland, KG ;
Bray, KR .
UROLOGY, 2000, 56 (02) :255-260
[8]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[9]   Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements [J].
Catalona, WJ ;
Smith, DS ;
Ornstein, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1452-1455
[10]   COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].
CATALONA, WJ ;
RICHIE, JP ;
AHMANN, FR ;
HUDSON, MA ;
SCARDINO, PT ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290